Tag: Boston Scientific

Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019

MARLBOROUGH, Mass., Jan. 14, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE:  BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company’s guidance range of 13 to 15 percent; approximately 14.1 percent on […]

Boston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19

Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical […]

Boston Scientific Announces Results For Third Quarter 2019

MARLBOROUGH, Mass., Oct. 23, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on a reported basis, 14.2 percent on an operational1 basis and 9.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP earnings […]

Boston Scientific Announces Positive Data from the EVOLVE Short DAPT study with the SYNERGY™ Bioabsorbable Polymer Stent

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after undergoing percutaneous coronary intervention SAN FRANCISCO and MARLBOROUGH, Mass., Sept. 26, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety […]

Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm […]

Boston Scientific Announces Results For Second Quarter 2019

MARLBOROUGH, Mass., July 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported […]

Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day

MARLBOROUGH, Mass., June 26, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline and strategic investments to enable improved clinical and economic outcomes, sustain category leadership […]

InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure

SOUTH SAN FRANCISCO–(BUSINESS WIRE)–InterVene Inc. today announced it has raised $15 million in a Series B financing round. The company’s BlueLeaf® Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) — the failure of venous valves in the legs — that does not require an implant. […]

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (OAC) – including direct oral anticoagulants (DOAC) and warfarin – for stroke risk reduction in patients with […]

Boston Scientific Receives U.S. FDA Approval for The VICI VENOUS STENT™ System

MARLBOROUGH, Mass., May 6, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked […]